Last Updated: November 8, 2026

METHYLPREDNISOLONE SODIUM SUCCINATE Drug Patent Profile

« Back to Dashboard

When do Methylprednisolone Sodium Succinate patents expire, and when can generic versions of Methylprednisolone Sodium Succinate launch?

Methylprednisolone Sodium Succinate is a drug marketed by Abraxis Pharm, Amneal, Bedford Labs, Elkins Sinn, Eugia Pharma, Fresenius Kabi Usa, Hikma, Intl Medication, Sagent Pharms Inc, Teva Parenteral, Tianjin Kingyork, and Watson Labs. and is included in thirty-three NDAs.

The generic ingredient in METHYLPREDNISOLONE SODIUM SUCCINATE is methylprednisolone sodium succinate. There is one drug master file entry for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the methylprednisolone sodium succinate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Methylprednisolone Sodium Succinate

A generic version of METHYLPREDNISOLONE SODIUM SUCCINATE was approved as methylprednisolone sodium succinate by FRESENIUS KABI USA on July 30^th, 2004.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for METHYLPREDNISOLONE SODIUM SUCCINATE?
What are the global sales for METHYLPREDNISOLONE SODIUM SUCCINATE?
What is Average Wholesale Price for METHYLPREDNISOLONE SODIUM SUCCINATE?

Summary for METHYLPREDNISOLONE SODIUM SUCCINATE

US Patents:	0
Applicants:	12
NDAs:	33
Finished Product Suppliers / Packagers:	8
Raw Ingredient (Bulk) Api Vendors:	48
Clinical Trials:	44
Patent Applications:	449
DailyMed Link:	METHYLPREDNISOLONE SODIUM SUCCINATE at DailyMed

Drug patent expirations by year for METHYLPREDNISOLONE SODIUM SUCCINATE

Recent Clinical Trials for METHYLPREDNISOLONE SODIUM SUCCINATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Second Affiliated Hospital, School of Medicine, Zhejiang University	PHASE4
The First Affiliated Hospital of Zhengzhou University	PHASE4
First Affiliated Hospital of Harbin Medical University	PHASE4

See all METHYLPREDNISOLONE SODIUM SUCCINATE clinical trials

Pharmacology for METHYLPREDNISOLONE SODIUM SUCCINATE

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for METHYLPREDNISOLONE SODIUM SUCCINATE

A01AC	Corticosteroids for local oral treatment
A01A	STOMATOLOGICAL PREPARATIONS
A01	STOMATOLOGICAL PREPARATIONS
A	Alimentary tract and metabolism

A07EA	Corticosteroids acting locally
A07E	INTESTINAL ANTIINFLAMMATORY AGENTS
A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A	Alimentary tract and metabolism

C05AA	Corticosteroids
C05A	AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
C05	VASOPROTECTIVES
C	Cardiovascular system

D07AA	Corticosteroids, weak (group I)
D07A	CORTICOSTEROIDS, PLAIN
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

D07AA	Corticosteroids, weak (group I)
D07A	CORTICOSTEROIDS, PLAIN
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

D07XA	Corticosteroids, weak, other combinations
D07X	CORTICOSTEROIDS, OTHER COMBINATIONS
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

D10AA	Corticosteroids, combinations for treatment of acne
D10A	ANTI-ACNE PREPARATIONS FOR TOPICAL USE
D10	ANTI-ACNE PREPARATIONS
D	Dermatologicals

H02AB	Glucocorticoids
H02A	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
H02	CORTICOSTEROIDS FOR SYSTEMIC USE
H	Systemic hormonal preparations, excluding sex hormones and insulins

H02AB	Glucocorticoids
H02A	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
H02	CORTICOSTEROIDS FOR SYSTEMIC USE
H	Systemic hormonal preparations, excluding sex hormones and insulins

R01AD	Corticosteroids
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

S01BA	Corticosteroids, plain
S01B	ANTIINFLAMMATORY AGENTS
S01	OPHTHALMOLOGICALS
S	Sensory organs

S01CB	Corticosteroids/antiinfectives/mydriatics in combination
S01C	ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION
S01	OPHTHALMOLOGICALS
S	Sensory organs

S02BA	Corticosteroids
S02B	CORTICOSTEROIDS
S02	OTOLOGICALS
S	Sensory organs

S03BA	Corticosteroids
S03B	CORTICOSTEROIDS
S03	OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
S	Sensory organs

US Patents and Regulatory Information for METHYLPREDNISOLONE SODIUM SUCCINATE

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Parenteral	METHYLPREDNISOLONE SODIUM SUCCINATE	methylprednisolone sodium succinate	INJECTABLE;INJECTION	081266-001	Nov 30, 1992		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Intl Medication	METHYLPREDNISOLONE SODIUM SUCCINATE	methylprednisolone sodium succinate	INJECTABLE;INJECTION	087812-001	Feb 9, 1983		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Watson Labs	METHYLPREDNISOLONE SODIUM SUCCINATE	methylprednisolone sodium succinate	INJECTABLE;INJECTION	086953-001	Jul 22, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Tianjin Kingyork	METHYLPREDNISOLONE SODIUM SUCCINATE	methylprednisolone sodium succinate	INJECTABLE;INJECTION	212396-001	Apr 20, 2021	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Watson Labs	METHYLPREDNISOLONE SODIUM SUCCINATE	methylprednisolone sodium succinate	INJECTABLE;INJECTION	087030-001	Jul 22, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Hikma	METHYLPREDNISOLONE SODIUM SUCCINATE	methylprednisolone sodium succinate	INJECTABLE;INJECTION	203125-001	Sep 26, 2022	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Intl Medication	METHYLPREDNISOLONE SODIUM SUCCINATE	methylprednisolone sodium succinate	INJECTABLE;INJECTION	087813-001	Feb 9, 1983		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.